Background: The aim of the study is to compare measured glomerular filtration rate by technetium radiolabled diethylene tiamine pentaacetic acid (mGFR DTPA) to estimated GFR (eGFR). Glomerular fi ltration rate (GFR) is estimated from serum creatinine (eGFR creatinine ), serum cystatin C (eGFR cystatin C ) and by combined equation (eGFR creatinine + cystatin C ). This study focuses on oncology patients considered for treatment with cis-diamminedichloroplatinum (cisplatin). We evaluated the impact of diff erent GFR methods on the reduction of cisplatin dose. Patients and Methods: The study population consisted of 112 consecutive oncology patients from oncology center treated in the town of Zlin in the Czech Republic, who were considered for cisplatin treatment. mGFR DTPA was performed by dynamic renal
Background
Therapeutic doses of drugs excreted by kidneys must be adjusted according to the glomerular fi ltration rate (GFR). The GFR is the most important parameter of kidney function. The decision GFR point of 1.0 ml/ s/ 1.73 m 2 is used for reduction of dose of drugs excreted by kidneys. The state of GFR below 1.0 ml/ s/ 1.73 m 2 for more than three consecutive months is also defi ned as chronic kidney disease (CKD) according to Kidney Disease Improving Global Outcomes (KDIGO) guide lines [1] . Cisplatin is a well-established chemotherapeutic agent for many solid tumors. This drug has multiple nephrotoxic side eff ects [2] . The dose of cisplatin must be decreased in correlation with the decline of GFR [3] .
Reduction of drug doses is a very important reason why we need a reliable method for the assessment of GFR.
Isotopic methods are also clinically available methods for the determination of GFR but are available only in specialized centers, are invasive, time consuming, have radiation burden and are not feasible for all patients.
Calculating clearance of some substances with measuring urine output is also diffi cult.
Estimating GFR from a serum endogenous substance without urine collection is another way to determine GFR. The serum creatinine and cystatin C are the most commonly established serum markers to the estimation of GFR. Creatinine is the waste product of muscle energy metabolism. It is produced at a constant rate. Cystatin C is produced by all nucleat ed cells at a constant rate [4] . Both creatinine and cystatin C methods have been standardized and CKD-EPI equations for estimation of GFR have been established [5] .
Oncology patients are a specifi c subgroup of patients. They are characterized by the burden of tumor mass and by often reduced muscle mass.
We compared mGFR DTPA and eGFR from serum creatinine and cystatin C using new CKD-EPI equations in oncology patients considered for treatment with cisplatin.
Oncologists reduce the dose of cis platin when the GFR is below 1.0 ml/ s/ 1.73 m 2 . We also evaluated impact of diff erent GFR methods on this therapeutic dose decision making.
Patients and methods

Patients
The study population consisted of 112 consecutive oncology patients from Oncology center of Tomas Bata regional hospital in the town of Zlin, who were considered for treatment with cisplatin.
Majority of patients (pts) had head and neck cancer (46 pts). One patient with metastatic bladder cancer was included (palliative chemotherapy), and fi ve other patients with urothelial carcinoma were treated in adjuvant setting (one patient treated with chemotherapy after nephrectomy, four pts with concomitant chemo-radiotherapy). The frequency of other tumors in descending order was as follows: 16 pts with cervical cancer, 11 pts with esophageal cancer, 9 pts with gastric cancer, 7 pts with testicular tumors (all of them in adjuvant setting), 5 pts with endometrial uterine cancer, 3 pts with cancer of biliary tract, 3 pts with occult primary cancer, 2 pts with anal cancer, 2 pts with malignant melanoma, 1 patient with lung cancer (non-small cell lung cancer), and 1 patient with squamous-cell gynecological cancer. Forty-seven of all patients were treated in palliative setting.
The study lasted from April 2012 to June 2013 and was approved by the Souhrn Východiska: Cílem práce je porovnat glomerulární fi ltraci měřenou izotopovou metodu (measured glomarular fi ltration rate -mGFR DTPA) a odhadovanou glomerulární fi ltraci (estimated GFR -eGFR). Glomerulární fi ltrace (GFR) je odhadovaná ze sérového kreatininu (eGFR creatinine ), sérového cystatinu C (eGFR cystatin C ) a pomocí kombinované rovnice (eGFR creatinine + cystatin C ). Studie se zaměřuje na onkologické pa cienty zvažované pro léčbu cis-diamindichlorplatinou (cisplatin). Hodnotili jsme dopad různých GFR metod na redukci dávky cisplatiny. Materiál a metody: Studovaná populace byla tvořena 112 po sobě jdoucími pa cienty z onkologického centra ve Zlíně v České republice, kteří byli zvažováni pro léčbu cisplatinou. mGFR DTPA byla provedena dynamickou renální scintigrafi í využívající kyselinu diethyltriaminopentaaoctovou (DTPA) značenou izotopem technecia The GFR results did not have a normal distribution, so we used nonparametric tests for data analysis.
The Friedman test was used for comparison of four medians.
The Spearman correlation analysis was performed for correlation among GFR methods.
The Bland-Altman plots were used for comparison of two GFR methods.
In 2012 the CKD-EPI Collaboration research group developed an equation for estimation of GFR from serum cystatin C (eGFR cystatin C ) and a combined equation for estimation from both serum creatinine and cystatin C (eGFR creatinine + cystatin C ) [5] .
Statistical methods
The D'Agostino-Pearson test was used to assess normal distribution of GFR results.
Ethics Committee of Tomas Bata regional hospital.
All patients had mGFR DTPA imaging, serum creatinine and serum cystatin C tests performed.
As for co morbid conditions, 53 pts had also arterial hypertension and 17 pts had diabetes mellitus. Nine patients had preexisting nephropathy (3 with hyperuricemia, 2 were after unilateral nephrectomy, 2 with hydroneph rosis solved with stenting or nephrostomia, 1 with chronic pyelonephritis, and 1 with nephrolithiasis). mGFR DTPA mGFR DTPA was performed at the department of nuclear medicine. The radioactive agent of 99m Tc DTPA was applied to patients in a single bolus injection without urine collection [6] .
Creatinine Serum creatinine was determined by enzymatic photometric method standardized against certifi ed reference material named NIST SRM 967 [7, 8] . The Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration research group devel oped equation for estimation of GFR from serum creatinine in 2009. It is named CKD-EPI equation (eGFR creatinine ) [9] .
Cystatin C Cystatin C was measured by immunoturbidimetric standardized method [10] . accurate or biased [1] . This may be the case in many oncology patients and our results confi rm it. Performance of reference methods, such as inulin clearance, is impractical in clinical practice. One of the methods for determining GFR is mGFR DTPA. Today, single bolus mGFR DTPA is reToday the KDIGO guidelines recommend the decrease of cisplatin dose when GFR is below 1.0 ml/ s/ 1.73 m 2 . eGFR creatinine and eGFR cystatin C are recommended only for clinically stable patients. The guidelines recommend using reference method in clinical situation where eGFR creatinine or eGFR cystatin C are in- The median of eGFR creatinine 1.460 ml/ s/ / 1.73 m 2 (1.210-1.660) was higher than mGFR DTPA (p < 0.05).
mGFR DTPA results would detect CKD and reduce cisplatin dose in 20 patients, eGFR cystatin C in 31 patients, eGFR creatinine in 10 patients and eGFR creatinine + cystatin C in 22 patients.
Correlations among GFR methods are shown in Tab. 2. Correlation analysis found no diff erence among correlation coeffi cients of mGFR DTPA and all eGFR's (p > 0.05).
The individual differences between mGFR and three estimated GFR's are displayed in Graphs 1-3.
Graph 1 shows high degree of individual diff erences between methods and the trend that in the range of GFR bel low 1.0 ml/ s/ 1.73 m 2 eGFR creatinine is more apparently higher than mGFR DTPA.
Graphs 2 and 3 show high degree of individual diff erences between methods and no trend.
Discussion
Population of 112 oncology patients with dia gnoses which require treatment with cisplatin was involved in this study. Because cisplatin is nephrotoxic, hydration and reduction of dose of cisplatin according to GFR are key stones of nephrotoxicity prevention.
The dose reduction of nephrotoxic drugs was historically calculated from serum creatinine according to the Cockcroft & Gault formula [11] .
Later, it was recommended to reduce the dose of cisplatin in patients with creatinine clearance 50-60 ml/ min. The cisplatin is not given to patients with clearance of creatinine below 40 ml/ min. But clearance of creatinine overestimates the true GFR [12] . Further, urine collections are cumbersome, and incomplete collections are frequent in clinical practice. All methods which we compare in this study do not require urine collection. We compared eGFR creatinine and eGFR cystatin C in 352 consecutive stable patients with CKD and found the Spearman correlation coeffi cient of 0.912 (p < 0.001). We used the same meth ods and equations as in this oncology patients study [25] . The Spearman cor relation coefficient between eGFR creatinine and eGFR cystatin C in this oncology patient cohort was 0.750 (p < 0.0001). It shows that correlation between these two methods of GFR is much better in stable patients with CKD than in oncology patients.
The limitation of this study is the absence of inulin reference method for determination of GFR and the limited number of patients. We also did not measure muscle mass in our patients.
Conclusions
Oncology patients are a very special group of patients who diff er from general population.
There are significant individual differences between mGFR DTPA and all eGFR's. It has an important impact on the detection rate of CKD and a potential drug dosage adjustment.
The median of eGFR cystatin C was lower than mGFR DTPA.
The median of eGFR creatinine was higher than mGFR DTPA.
